Technology and target group: In Parkinsons disease, the brain cells that produce dopamine die. Approximately 15 000 patients in Sweden have Parkinsons disease. In its early stages, the disease can often be treated successfully by drugs. However, in most patients the disease progresses after a few years to a stage with complications where drugs no longer have a sufficient effect. In patients wit...

Apomorphine and certain ergot alkaloids (bromocriptine, lisuride and pergolide) have been available for several decades; for the last few years, they were joined by newer dopamine agonists (cabergoline, pramipexole and ropinirole) most of them are non-ergolines. Each of these dopamine agonists has its own pharmacological characteristics and occupies a place in the pharmacotherapy of Parkinsons ...

Home based objective measures of bradykinesia and dyskinesia will be important in managing Parkinsons Disease (PD). The Aim of this paper was to further validate the Parkinsons Kinetigraph system as a tool for measuring bradykinesia and dyskinesia by examining its capacity capture the effect of therapeutic interventions, detect bradykinesia and asymmetry in a newly diagnosed patients, and corre...

Like many neurodegenerative diseases, the clinical symptoms of Parkinsons disease (PD) do not manifest until significant progression of the disease has already taken place, motivating the need for sensitive biomarkers of the disease. While structural imaging is a potentially attractive method due to its widespread availability and non-invasive nature, global morphometric measures (e.g., volume)...